Aug 13, 2026 08:05AM
Aug 13, 2026 08:05AM
Aug 4, 2026 04:01PM
Jul 1, 2026 08:05AM
Jul 1, 2026 08:05AM
Jun 16, 2026 04:02PM
Jun 16, 2026 04:01PM Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
May 21, 2026 05:36PM
May 21, 2026 05:17PM
May 12, 2026 07:02AM
May 12, 2026 07:00AM
May 5, 2026 04:01PM
Mar 31, 2026 08:07AM
Mar 31, 2026 08:05AM Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Mar 3, 2026 04:01PM
Jan 12, 2026 08:07AM
Jan 12, 2026 08:05AM
Dec 7, 2025 09:30AM
Dec 7, 2025 09:30AM
Nov 17, 2025 08:05AM
Nov 17, 2025 08:05AM Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Nov 4, 2025 04:01PM
Nov 3, 2025 09:05AM
Oct 9, 2025 06:42AM
Oct 8, 2025 08:05AM
Oct 8, 2025 08:05AM
Aug 5, 2025 04:01PM
May 22, 2025 05:21PM Rigel Pharma (RIGL) announces seven upcoming poster presentations at 2025 ASCO
May 22, 2025 05:20PM
May 6, 2025 04:01PM
Mar 27, 2025 08:05AM
Mar 27, 2025 08:05AM
Mar 10, 2025 08:07AM
Mar 10, 2025 08:05AM
Mar 5, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Rigel Pharmaceuticals (RIGL)
Mar 4, 2025 04:01PM
Jan 22, 2025 08:05AM
Jan 22, 2025 08:05AM
Jan 13, 2025 08:05AM
Jan 13, 2025 08:05AM
Jan 9, 2025 08:05AM
Dec 9, 2024 12:02PM Rigel Pharma (RIGL) Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Dec 9, 2024 12:02PM
Dec 2, 2024 08:05AM
Dec 2, 2024 08:05AM
Nov 7, 2024 04:01PM
Nov 5, 2024 09:05AM
Oct 24, 2024 04:36PM
Oct 24, 2024 04:35PM Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
Oct 16, 2024 10:01AM

329,074 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All